A detailed history of Verition Fund Management LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 67,502 shares of CPRX stock, worth $1.49 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
67,502
Previous 24,055 180.62%
Holding current value
$1.49 Million
Previous $372,000 260.48%
% of portfolio
0.01%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$15.19 - $21.35 $659,959 - $927,593
43,447 Added 180.62%
67,502 $1.34 Million
Q2 2024

Aug 14, 2024

BUY
$14.68 - $16.92 $353,127 - $407,010
24,055 New
24,055 $372,000
Q3 2022

Nov 14, 2022

BUY
$7.06 - $15.52 $70,755 - $155,541
10,022 New
10,022 $129,000

Others Institutions Holding CPRX

About CATALYST PHARMACEUTICALS, INC.


  • Ticker CPRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 102,820,000
  • Market Cap $2.27B
  • Description
  • Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...
More about CPRX
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.